
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
TARGET PharmaSolutions, Inc., a company focused on real-world evidence, launched its latest large-scale observational study, TARGET-DERM. The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis (AD/eczema). and vitiligo (loss of skin pigment).
Read the full release






